Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1362Gemcitabine 1235Bevacizumab 1226Paclitaxel 1214Radiotherapy 1176Docetaxel 1080pembrolizumab 1029Oxaliplatin 936Capecitabine 902Fluorouracil 833Rituximab 729Doxorubicin 684Nivolumab 679Dexamethasone 667Etoposide 660Irinotecan 622Leucovorin 576Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 470Cytarabine 467Magnetic Resonance Spectroscopy 461Filgrastim 446Prednisone 433Specimen Handling 411Lenalidomide 410Vincristine 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × apraclonidine × Clear all
NCT05045248 2021-09-16

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

American University of Beirut Medical Center

Phase 2 Completed
10 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡